Present status of photodynamic therapy for high-grade dysplasia in Barrett's esophagus

Herbert C. Wolfsen

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Goals: Review recent developments in Barrett's dysplasia including regulatory approval of porfimer sodium photodynamic therapy. Background: Barrett's esophagus is thought to be the result of long-standing gastroesophageal reflux disease and is known to be the most important risk factor for the development of esophageal adenocarcinoma. The natural history of Barrett's esophagus is not well known, but the annual incidence of invasive adenocarcinoma is estimated to be 0.5% (reported range, 0.2%-2.0%). This represents an increased risk for esophageal cancer of 30 to 60 times higher than normal subjects. As for colorectal cancer, malignant degeneration is Barrett's esophagus is thought to occur through a continuum of histologic stages: metaplasia, dysplasia and neoplasia. Barrett's high-grade dysplasia (formerly referred to as carcinoma in situ) is the histologic stage of disease that immediately precedes the development of invasive carcinoma. Conclusions: Previously, Barrett's high-grade dysplasia patients were routinely referred for esophageal resection surgery based upon the assumption of inevitable progression to cancer, the high rate of undiagnosed synchronous cancers, and few treatment alternatives. Important developments in Barrett's high-grade dysplasia include recent publications regarding the natural history of Barrett's high-grade dysplasia and the regulatory approval for endoscopic ablation therapy using porfimer sodium photodynamic therapy (Photofrin PDT).

Original languageEnglish (US)
Pages (from-to)189-202
Number of pages14
JournalJournal of Clinical Gastroenterology
Volume39
Issue number3
DOIs
StatePublished - Mar 2005

Fingerprint

Dihematoporphyrin Ether
Barrett Esophagus
Photochemotherapy
Adenocarcinoma
Neoplasms
Carcinoma in Situ
Metaplasia
Esophageal Neoplasms
Gastroesophageal Reflux
Natural History
Colorectal Neoplasms
Carcinoma
Incidence
Therapeutics

Keywords

  • Amino levulinic acid
  • Endoscopic mucosal resection
  • Endoscopic ultrasound
  • Photodynamic therapy
  • Porfimer sodium

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Present status of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. / Wolfsen, Herbert C.

In: Journal of Clinical Gastroenterology, Vol. 39, No. 3, 03.2005, p. 189-202.

Research output: Contribution to journalArticle

@article{54c474a6e71d4806a3c0592512c3c4fa,
title = "Present status of photodynamic therapy for high-grade dysplasia in Barrett's esophagus",
abstract = "Goals: Review recent developments in Barrett's dysplasia including regulatory approval of porfimer sodium photodynamic therapy. Background: Barrett's esophagus is thought to be the result of long-standing gastroesophageal reflux disease and is known to be the most important risk factor for the development of esophageal adenocarcinoma. The natural history of Barrett's esophagus is not well known, but the annual incidence of invasive adenocarcinoma is estimated to be 0.5{\%} (reported range, 0.2{\%}-2.0{\%}). This represents an increased risk for esophageal cancer of 30 to 60 times higher than normal subjects. As for colorectal cancer, malignant degeneration is Barrett's esophagus is thought to occur through a continuum of histologic stages: metaplasia, dysplasia and neoplasia. Barrett's high-grade dysplasia (formerly referred to as carcinoma in situ) is the histologic stage of disease that immediately precedes the development of invasive carcinoma. Conclusions: Previously, Barrett's high-grade dysplasia patients were routinely referred for esophageal resection surgery based upon the assumption of inevitable progression to cancer, the high rate of undiagnosed synchronous cancers, and few treatment alternatives. Important developments in Barrett's high-grade dysplasia include recent publications regarding the natural history of Barrett's high-grade dysplasia and the regulatory approval for endoscopic ablation therapy using porfimer sodium photodynamic therapy (Photofrin PDT).",
keywords = "Amino levulinic acid, Endoscopic mucosal resection, Endoscopic ultrasound, Photodynamic therapy, Porfimer sodium",
author = "Wolfsen, {Herbert C.}",
year = "2005",
month = "3",
doi = "10.1097/01.mcg.0000152748.56902.02",
language = "English (US)",
volume = "39",
pages = "189--202",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Present status of photodynamic therapy for high-grade dysplasia in Barrett's esophagus

AU - Wolfsen, Herbert C.

PY - 2005/3

Y1 - 2005/3

N2 - Goals: Review recent developments in Barrett's dysplasia including regulatory approval of porfimer sodium photodynamic therapy. Background: Barrett's esophagus is thought to be the result of long-standing gastroesophageal reflux disease and is known to be the most important risk factor for the development of esophageal adenocarcinoma. The natural history of Barrett's esophagus is not well known, but the annual incidence of invasive adenocarcinoma is estimated to be 0.5% (reported range, 0.2%-2.0%). This represents an increased risk for esophageal cancer of 30 to 60 times higher than normal subjects. As for colorectal cancer, malignant degeneration is Barrett's esophagus is thought to occur through a continuum of histologic stages: metaplasia, dysplasia and neoplasia. Barrett's high-grade dysplasia (formerly referred to as carcinoma in situ) is the histologic stage of disease that immediately precedes the development of invasive carcinoma. Conclusions: Previously, Barrett's high-grade dysplasia patients were routinely referred for esophageal resection surgery based upon the assumption of inevitable progression to cancer, the high rate of undiagnosed synchronous cancers, and few treatment alternatives. Important developments in Barrett's high-grade dysplasia include recent publications regarding the natural history of Barrett's high-grade dysplasia and the regulatory approval for endoscopic ablation therapy using porfimer sodium photodynamic therapy (Photofrin PDT).

AB - Goals: Review recent developments in Barrett's dysplasia including regulatory approval of porfimer sodium photodynamic therapy. Background: Barrett's esophagus is thought to be the result of long-standing gastroesophageal reflux disease and is known to be the most important risk factor for the development of esophageal adenocarcinoma. The natural history of Barrett's esophagus is not well known, but the annual incidence of invasive adenocarcinoma is estimated to be 0.5% (reported range, 0.2%-2.0%). This represents an increased risk for esophageal cancer of 30 to 60 times higher than normal subjects. As for colorectal cancer, malignant degeneration is Barrett's esophagus is thought to occur through a continuum of histologic stages: metaplasia, dysplasia and neoplasia. Barrett's high-grade dysplasia (formerly referred to as carcinoma in situ) is the histologic stage of disease that immediately precedes the development of invasive carcinoma. Conclusions: Previously, Barrett's high-grade dysplasia patients were routinely referred for esophageal resection surgery based upon the assumption of inevitable progression to cancer, the high rate of undiagnosed synchronous cancers, and few treatment alternatives. Important developments in Barrett's high-grade dysplasia include recent publications regarding the natural history of Barrett's high-grade dysplasia and the regulatory approval for endoscopic ablation therapy using porfimer sodium photodynamic therapy (Photofrin PDT).

KW - Amino levulinic acid

KW - Endoscopic mucosal resection

KW - Endoscopic ultrasound

KW - Photodynamic therapy

KW - Porfimer sodium

UR - http://www.scopus.com/inward/record.url?scp=14144250646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14144250646&partnerID=8YFLogxK

U2 - 10.1097/01.mcg.0000152748.56902.02

DO - 10.1097/01.mcg.0000152748.56902.02

M3 - Article

VL - 39

SP - 189

EP - 202

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 3

ER -